Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder

NCT02414503 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Autism Spectrum Disorder

Interventions

DRUG: 8IU intranasal oxytocin
DRUG: 24IU intranasal oxytocin
DRUG: Placebo
DEVICE: OptiNose Breath Powered Bi

Sponsor

OptiNose AS

Collaborators

[object Object]
[object Object]